Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-resistance in T-cell Acute Lymphoblastic Leukemia

Jingliao Zhang,Yongjuan Duan,Peng Wu,Yanxia Chang,Yue Wang,Tianyuan Hu,Chao Liu,Xiaoyan Chen,Suyu Zong,Xiaoli Chen,Yangping Wu,Linlin Jin,Yang Lan,Xiaoming Liu,Xuelian Cheng,Feng Ding,Tianyu Li,Xiaojuan Chen,Ye Guo,Yumei Chen,Wenyu Yang,Li Zhang,Yao Zou,Tao Cheng,Xiao-Fan Zhu,Yingchi Zhang
DOI: https://doi.org/10.1182/blood.2023020490
IF: 20.3
2023-10-08
Blood
Abstract:Two leukemic evolutionary patterns, ȁC;clonal shiftȁD; and ȁC;clonal driftȁD; are unveiled in relapsed T-ALL via single-cell multiomics profiling. High RNA-binding protein MSI2 level accounts for persistent clones at relapse through the posttranscriptional regulation of MYC in T-ALL. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer with resistant clonal propagation in recurrence. We performed high-throughput droplet-based 5′-single-cell RNA with paired T-cell receptor (scTCR) sequencing of paired diagnosis-relapse (Dx_Rel) T-ALL samples to dissect the clonal diversities. Two leukemic evolutionary patterns, "clonal shift" and "clonal drift" were unveiled. Targeted single-cell DNA sequencing of paired Dx_Rel T-ALL samples further corroborated the existence of the two contrasting clonal evolution patterns, revealing that dynamic transcriptional variation might cause the mutationally static clones to evolve chemo-resistance. Analysis of commonly enriched drifted gene signatures showed expression of the RNA-binding protein MSI2 was significantly upregulated in the persistent TCR clonotypes at relapse. Integrated in vitro and in vivo functional studies suggested that MSI2 contributed to the proliferation of T-ALL and promoted chemo-resistance through the posttranscriptional regulation of MYC, pinpointing MSI2 as an informative biomarker and novel therapeutic target in T-ALL.
hematology
What problem does this paper attempt to address?